Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.59 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.59 |
| ▸ | HPSE | Q9Y251 | 9/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14626706 | 0.92 | ITGB1 (0.57) | ITGB1ITGA4HPSEPTGDR2IDO1 | |
| SCHEMBL2434541 | 0.92 | ITGB1 (0.60) | ITGB1ITGA4HPSEPTGDR2S1PR1 | |
| SCHEMBL14592396 | 0.89 | ITGB1 (0.57) | ITGB1ITGA4HPSEIDO1TDO2 | |
| SCHEMBL14591805 | 0.89 | ITGB1 (0.55) | ITGB1ITGA4HPSEPTGDR2IDO1 | |
| SCHEMBL2436328 | 0.87 | ITGB1 (0.57) | ITGB1ITGA4HPSES1PR1S1PR3 | |
| SCHEMBL12327757 | 0.86 | ITGB1 (0.51) | ITGB1ITGA4IDO1TDO2S1PR1 | |
| SCHEMBL14627048 | 0.84 | ITGB1 (0.58) | ITGB1ITGA4HPSEPTGDR2S1PR1 | |
| SCHEMBL2429639 | 0.82 | ITGB1 (0.59) | ITGB1ITGA4HPSEPTGDR2MET | |
| SCHEMBL14591801 | 0.82 | ITGB1 (0.56) | ITGB1ITGA4PTGDR2S1PR1S1PR3 | |
| SCHEMBL2435546 | 0.81 | ITGB1 (0.48) | ITGB1ITGA4IDO1TDO2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885HPSE 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.